|
|
ImmunoGen, Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: Buyout target articleMirvetuximab's focus on ovarian cancer overlaps with BMY's Abraxane. AMGN/GILD/MRK also expanding into oncology and ovarian could be a medium fit for IMGN. Makes sense if you already have a sales channel in gynecology/oncology. Both Breast and ovarian cancer associated with BRCA1 or BRCA2 mutations. Roche Avastin is the #1 selling Ovarian Cancer Treatment. They also have Perjeta and Herceptin for Breast. Major players in the ovarian cancer drugs market are AstraZeneca, Roche, GSK/Tesaro, Clovis Oncology, Boehringer Ingelheim, Amgen, GlaxoSmithKline, Roche AG, Bristol-Myers Squibb and Eli Lilly and Company. Can probably take GILD off the list since they already own an ADC technology via Immunomedics. BMY, Roche or GSK probably make the most sense as they all serve this market and can use an ADC platform. |
||||||||||||
|
|
return to message board, top of board |
